Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

ORGO stock hub

Organogenesis Holdings Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ORGOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

305M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ORGO

In the news

Latest news · ORGO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE0.7

P25 -105.6P50 -46.5P75 -3.1

ROIC2.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ORGO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

230

Groups with data

Currency

USD

Showing 230 of 230 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001661181
Company name	Organogenesis Holdings Inc.
Country	United States
Country code	US
Cusip	68621F102
Employees	854
Employees Change	-15%
Employees Change Percent	-1.73
Enterprise value	$284.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Isin	US68621F1021
Last refreshed	2026-05-10
Market cap	$305M
Market cap category	Small-Cap
Price	$2.37
Price currency	USD
Rev Per Employee	602,697.89x
Sector	Healthcare
Sic	2834
Symbol	ORGO
Website	https://organogenesis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-4.77%
EV Sales Forward	0.69x
EV/EBIT	17.02x
EV/EBITDA	6.95x
EV/FCF	16.65x
EV/Sales	0.55x
FCF yield	5.6%
P/B ratio	1.25x
P/S ratio	0.59x
PE Ratio5 Y	32.75x
PS Forward	0.75x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	3.25%
EBITDA Margin	7.95%
FCF margin	3.32%
Gross margin	73.89%
Gross Profit	$380.3M
Gross Profit Growth	9.29%
Gross Profit Growth Q	-81.81%
Gross Profit Growth3 Y	2.33%
Gross Profit Growth5 Y	5.93%
Net Income	$-14.5M
Net Income Growth Years	1%
Pretax Margin	0.83%
Profit Margin	0.53%
Profit Per Employee	$-17,033
Profitable Years	1
ROA	2.12
Roa5y	5.59
ROCE	3.76
ROE	0.73
Roe5y	13.28
ROIC	2.72
Roic5y	13.27

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-54.27%
Cagr3y	3.79%
Cagr5y	-35.46%
EPS Growth Years	1
FCF Growth5 Y	41.07%
OCF Growth	593.42%
OCF Growth3 Y	18.74%
OCF Growth5 Y	7.47%
Revenue Growth	12.2x
Revenue Growth Q	-57.06x
Revenue Growth Years	2x
Revenue Growth3 Y	3.71x
Revenue Growth5 Y	6.31x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.04
Assets	$520M
Cash	$91.4M
Current Assets	$268.5M
Current Liabilities	$76M
Debt	$70.9M
Debt EBITDA	$1.12
Debt Equity	$0.19
Debt FCF	$4.15
Equity	$381.3M
Liabilities	$138.6M
Long Term Assets	$251.5M
Long Term Liabilities	$62.6M
Net Cash	$20.5M
Net Cash By Market Cap	$6.73
Net Cash Growth	-69.53%
Net Debt EBITDA	$-0.5
Net Debt Equity	$-0.05
Net Debt FCF	$-1.2
Tangible Book Value	$212.3M
Tangible Book Value Per Share	$1.65
WACC	9.3

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.53
Inventory Turnover	4.65
Net Working Capital	$110.8M
Quick ratio	2.74
Working Capital	$192.5M
Working Capital Turnover	$2.6

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.43%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-54.25%
200-day SMA	4.07
3Y total return	11.79%
50-day SMA	2.51
50-day SMA vs 200-day SMA	50under200
5Y total return	-88.79%
All Time High	310.9
All Time High Change	-99.24%
All Time High Date	2019-01-09
All Time Low	1.8
All Time Low Change	32.03%
All Time Low Date	2023-04-26
ATR	0.18
Beta	1.31
Beta1y	1.61
Beta2y	1.73
Ch YTD	-54.25
High	2.46
High52	7.08
High52 Date	2025-11-11
High52ch	-66.51%
Low	2.04
Low52	2.04
Low52 Date	2026-05-08
Low52ch	16.18%
Ma50ch	-5.46%
Premarket Change Percent	-18.97
Premarket Price	$2.05
Premarket Volume	313,861
Price vs 200-day SMA	-41.77%
RSI	42.96
RSI Monthly	42.1
RSI Weekly	35.49
Sharpe ratio	-0.48x
Sortino ratio	-0.62
Total Return	2.43%
Tr YTD	-54.25
Tr1m	4.87%
Tr1w	-7.78%
Tr3m	-37.14%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.29
Earnings Revenue Estimate	43,300,000x
Earnings Revenue Estimate Growth	-50.06x
Operating Income	$16.7M
Operating Income Growth	221.9
Operating Income Growth3 Y	-9.23
Operating Income Growth5 Y	-21.39
Operating margin	3.25
Price target	$8.5
Price Target Change	$259

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	49,200,458%
Float Percent	38.24%
Net Borrowing	-10,726,000
Shares Insiders	38.92%
Shares Institutions	44.04%
Shares Out	128,674,548
Shares Qo Q	-3.34%
Shares Yo Y	-2.43%
Short Float	26.62%
Short Ratio	6.81
Short Shares	10.18

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$3.5M
Average Volume	1,395,553.1x
Bv Per Share	1.9
CAPEX	$-13.7M
Ch1m	4.87
Ch1w	-7.78
Ch1y	-54.25
Ch3m	-37.14
Ch3y	11.79
Ch5y	-88.79
Ch6m	-57.9
Change	-6.32%
Change From Open	16.18
Close	2.53
Days Gap	-19.37
Depreciation Amortization	24,192,000
Dollar Volume	7,027,526.4
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$16.7M
EBITDA	$40.9M
EPS	$-0.12
F Score	4
FCF	$17.1M
FCF EV Yield	6.01x
FCF Per Share	$0.13
Financing CF	-35,517,000
Fiscal Year End	December
Founded	1,985
Goodwill	28,772,000
Income Tax	$1.6M
Investing CF	-13,671,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	3.86
Ma150ch	-38.52%
Ma20	2.46
Ma20ch	-3.62%
Net CF	-18,435,000
Next Earnings Date	2026-08-06
Open	2.04
Optionable	Yes
P FCF Ratio	17.85
P OCF Ratio	9.92
Position In Range	78.57
Post Close	2.37
Postmarket Change Percent	-1.27
Postmarket Price	$2.34
Ppne	157,820,000
Pre Close	2.53
Price Date	2026-05-08
Price EBITDA	$7.46
Ptbv Ratio	1.44
Relative Volume	2.12x
Revenue	514,704,000x
SBC By Revenue	2.64x
Share Based Comp	13,567,000
Tax By Revenue	0.3x
Tax Rate	36.47%
Tr6m	-57.9%
Us State	Massachusetts
Volume	2,965,201
Z Score	3.69

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ORGO pay a dividend?

Capital-return profile for this ticker.

Performance

ORGO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ORGO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+44.0%

Float: +38.2% of shares outstanding

Insider ownership

+38.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ORGO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.0

Neutral momentum band

Price vs 200-day MA

-41.8%

50/200-day relationship not available

Beta (5Y)

1.31

More volatile than the market

Sharpe ratio

-0.48

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ORGO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ORGO stock rating?

Organogenesis Holdings Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ORGO analysis?

The full report lives at /stocks/ORGO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ORGO?

The latest report frames ORGO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ORGO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.